Genmab A/S (NASDAQ:GMAB) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a report released on Wednesday, Benzinga reports. HC Wainwright currently has a $50.00 target price on the stock.

Several other equities research analysts have also commented on the stock. Truist Financial reiterated a buy rating and set a $50.00 price target on shares of Genmab A/S in a research note on Tuesday. Citigroup lowered shares of Genmab A/S from a neutral rating to a sell rating in a research note on Monday, January 22nd. UBS Group upgraded shares of Genmab A/S from a neutral rating to a buy rating in a research note on Wednesday, December 6th. Morgan Stanley restated an underweight rating on shares of Genmab A/S in a research note on Tuesday. Finally, BMO Capital Markets upgraded shares of Genmab A/S from a market perform rating to an outperform rating and lifted their price objective for the company from $46.00 to $48.00 in a research note on Friday, February 23rd. Three analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of Hold and a consensus target price of $48.50.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $30.63 on Wednesday. The stock has a market capitalization of $20.24 billion, a P/E ratio of 31.91, a PEG ratio of 1.40 and a beta of 0.98. The company has a 50 day moving average price of $28.85 and a 200 day moving average price of $31.10. Genmab A/S has a fifty-two week low of $26.32 and a fifty-two week high of $42.99.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 14th. The company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.34 by $0.02. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. The company had revenue of $675.29 million during the quarter, compared to analysts’ expectations of $678.14 million. Research analysts forecast that Genmab A/S will post 1.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors have recently modified their holdings of the company. Rockefeller Capital Management L.P. raised its position in shares of Genmab A/S by 1.7% in the first quarter. Rockefeller Capital Management L.P. now owns 18,508 shares of the company’s stock valued at $698,000 after buying an additional 310 shares during the last quarter. Ameriprise Financial Inc. increased its position in Genmab A/S by 5.7% during the third quarter. Ameriprise Financial Inc. now owns 6,268 shares of the company’s stock worth $221,000 after purchasing an additional 337 shares during the last quarter. Geode Capital Management LLC increased its position in Genmab A/S by 1.0% during the second quarter. Geode Capital Management LLC now owns 41,715 shares of the company’s stock worth $1,586,000 after purchasing an additional 408 shares during the last quarter. HBK Sorce Advisory LLC increased its position in Genmab A/S by 4.8% during the third quarter. HBK Sorce Advisory LLC now owns 9,139 shares of the company’s stock worth $322,000 after purchasing an additional 419 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in Genmab A/S by 86.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock worth $38,000 after purchasing an additional 498 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.